NCT05844046View on ClinicalTrials.gov

Sequential or Up-front Triple Treatment With Durvalumab, Tremelimumab and Bevacizumab for Non-resectable Hepatocellular Carcinoma (HCC) Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

April 6, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Hepatocellular Carcinoma
Interventions
BIOLOGICAL

durvalumab, tremelimumab, bevacizumab

durvalumab, tremelimumab and bevacizumab will be administered in the respective arms either as up-front triple treatment or as combined treatment with durvalumab and tremelimumab followed by the addition of bevacizumab

Trial Locations (3)

81377

RECRUITING

Hospital of the University of Munich, Munich

81675

RECRUITING

Klinikum Rechts der Isar of the Technical University Munich, Munich

Unknown

RECRUITING

Würzburg University Hospital, Würzburg

All Listed Sponsors
lead

Enrico De Toni

OTHER